Sareum Holdings

SAR · AIM · Health Care · mcap £43m · 27.5p

Beta Briefing, track record and bull & bear case are not ready for Sareum Holdings yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 37 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 08:35

All · 18 Key · 15

Date	Type	Announcement	Day
08 Oct 26		Capital Access Window - Sareum Holdings Plc ORDINARY SHARES OF GBP 0.0125 EACH, FULLY PAID	+0.0%
08 Oct 26		Capital Access Window Cambridge, UK, 8 October 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today, announces its intention to uti	+0.0%
02 Sep 26		Exercise of Warrants Cambridge, UK, 2 September 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received noti	+0.0%
19 Aug 26		Exercise of Warrants Cambridge, UK, 19 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notice	−3.4%
07 Aug 26		Exercise of Warrants Cambridge, UK, 7 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices	+0.0%
20 Jul 26		Completion of Dosing in Toxicology Programme Completion of Dosing in Phase 2-Enabling Toxicology Programme for SDC-1801	+4.2%
22 Jun 26		Publication of Phase 1 data on SDC-1801 in BJCP Publication of Phase 1 clinical data on SDC-1801 in British Journal of Clinical Pharmacology	+7.0%
01 May 26		Exercise of Warrants Cambridge, UK, 1 May 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notice to	−1.2%
12 Mar 26	Results	Half-year Results Half-Year Report for the Six Months Ended 31 December 2025	+7.1%
03 Mar 26	Routine	Notice of Results and Investor Presentation
17 Feb 26		Restart of Phase 2-enabling toxicology programme Restart of Phase 2-enabling toxicology programme for SDC-1801	−5.6%
09 Dec 25		Result of AGM Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AG	+0.0%
09 Dec 25		Annual General Meeting Statement Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer publishes an update on operations and	+0.0%
17 Nov 25	Routine	Notice of AGM, Annual Report and Accounts
30 Oct 25		Appointment of Joint Corporate Broker Cambridge, UK, 30 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointme	+0.0%
23 Oct 25	Results	Final Results Preliminary Results for the Year Ended 30 June 2025	+17.9%
10 Oct 25		Update on toxicology study for SDC-1801 Cambridge, UK, 10 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has discontinued i	−22.1%
07 Oct 25	Routine	Notice of Results and Investor Presentation

Company filings. Not investment advice.